Cargando…

Preferred practice guidelines for retinopathy of prematurity screening during the COVID-19 pandemic

Retinopathy of prematurity (ROP) is the leading cause of preventable infant blindness in the world and predominantly affects babies who are born low birth weight and premature. India has the largest number of surviving preterm births born annually. ROP blindness can be largely prevented if there is...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinekar, Anand, Azad, Rajvardhan, Dogra, Mangat Ram, Jalali, Subhadra, Bhende, Pramod, Chandra, Parijat, Venkatapathy, Narendran, Kulkarni, Sucheta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134152/
https://www.ncbi.nlm.nih.gov/pubmed/35663008
http://dx.doi.org/10.5409/wjcp.v11.i3.215
_version_ 1784713730511077376
author Vinekar, Anand
Azad, Rajvardhan
Dogra, Mangat Ram
Jalali, Subhadra
Bhende, Pramod
Chandra, Parijat
Venkatapathy, Narendran
Kulkarni, Sucheta
author_facet Vinekar, Anand
Azad, Rajvardhan
Dogra, Mangat Ram
Jalali, Subhadra
Bhende, Pramod
Chandra, Parijat
Venkatapathy, Narendran
Kulkarni, Sucheta
author_sort Vinekar, Anand
collection PubMed
description Retinopathy of prematurity (ROP) is the leading cause of preventable infant blindness in the world and predominantly affects babies who are born low birth weight and premature. India has the largest number of surviving preterm births born annually. ROP blindness can be largely prevented if there is a robust screening program which detects treatment requiring disease in time. ROP treatment must be provided within 48 h of reaching this threshold of treatment making it a relative emergency. During the severe acute respiratory syndrome-coronavirus disease 2019 pandemic in 2020 ROP screening was disrupted throughout the world due to lockdowns and restriction of movement of these infants, their families, specialists and healthcare workers. The Indian ROP Society issued guidelines for ROP screening and treatment in March 2020, which was aimed at preserving the chain-of-care despite the potential limitations and hazards during the (ongoing) pandemic. This preferred practice guideline is summarized in this manuscript.
format Online
Article
Text
id pubmed-9134152
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-91341522022-06-04 Preferred practice guidelines for retinopathy of prematurity screening during the COVID-19 pandemic Vinekar, Anand Azad, Rajvardhan Dogra, Mangat Ram Jalali, Subhadra Bhende, Pramod Chandra, Parijat Venkatapathy, Narendran Kulkarni, Sucheta World J Clin Pediatr Guidelines Retinopathy of prematurity (ROP) is the leading cause of preventable infant blindness in the world and predominantly affects babies who are born low birth weight and premature. India has the largest number of surviving preterm births born annually. ROP blindness can be largely prevented if there is a robust screening program which detects treatment requiring disease in time. ROP treatment must be provided within 48 h of reaching this threshold of treatment making it a relative emergency. During the severe acute respiratory syndrome-coronavirus disease 2019 pandemic in 2020 ROP screening was disrupted throughout the world due to lockdowns and restriction of movement of these infants, their families, specialists and healthcare workers. The Indian ROP Society issued guidelines for ROP screening and treatment in March 2020, which was aimed at preserving the chain-of-care despite the potential limitations and hazards during the (ongoing) pandemic. This preferred practice guideline is summarized in this manuscript. Baishideng Publishing Group Inc 2022-05-09 /pmc/articles/PMC9134152/ /pubmed/35663008 http://dx.doi.org/10.5409/wjcp.v11.i3.215 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Guidelines
Vinekar, Anand
Azad, Rajvardhan
Dogra, Mangat Ram
Jalali, Subhadra
Bhende, Pramod
Chandra, Parijat
Venkatapathy, Narendran
Kulkarni, Sucheta
Preferred practice guidelines for retinopathy of prematurity screening during the COVID-19 pandemic
title Preferred practice guidelines for retinopathy of prematurity screening during the COVID-19 pandemic
title_full Preferred practice guidelines for retinopathy of prematurity screening during the COVID-19 pandemic
title_fullStr Preferred practice guidelines for retinopathy of prematurity screening during the COVID-19 pandemic
title_full_unstemmed Preferred practice guidelines for retinopathy of prematurity screening during the COVID-19 pandemic
title_short Preferred practice guidelines for retinopathy of prematurity screening during the COVID-19 pandemic
title_sort preferred practice guidelines for retinopathy of prematurity screening during the covid-19 pandemic
topic Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134152/
https://www.ncbi.nlm.nih.gov/pubmed/35663008
http://dx.doi.org/10.5409/wjcp.v11.i3.215
work_keys_str_mv AT vinekaranand preferredpracticeguidelinesforretinopathyofprematurityscreeningduringthecovid19pandemic
AT azadrajvardhan preferredpracticeguidelinesforretinopathyofprematurityscreeningduringthecovid19pandemic
AT dogramangatram preferredpracticeguidelinesforretinopathyofprematurityscreeningduringthecovid19pandemic
AT jalalisubhadra preferredpracticeguidelinesforretinopathyofprematurityscreeningduringthecovid19pandemic
AT bhendepramod preferredpracticeguidelinesforretinopathyofprematurityscreeningduringthecovid19pandemic
AT chandraparijat preferredpracticeguidelinesforretinopathyofprematurityscreeningduringthecovid19pandemic
AT venkatapathynarendran preferredpracticeguidelinesforretinopathyofprematurityscreeningduringthecovid19pandemic
AT kulkarnisucheta preferredpracticeguidelinesforretinopathyofprematurityscreeningduringthecovid19pandemic